Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR 10 versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR 10 versus SULFALAR.
SULFAIR 10 vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
5 mg orally once daily, taken at bedtime.
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)